AMLX
Price
$4.61
Change
+$0.03 (+0.66%)
Updated
May 9 closing price
Capitalization
410.94M
88 days until earnings call
ERAS
Price
$1.39
Change
-$0.00 (-0.00%)
Updated
May 9 closing price
Capitalization
393.77M
One day until earnings call
Ad is loading...

AMLX vs ERAS

Header iconAMLX vs ERAS Comparison
Open Charts AMLX vs ERASBanner chart's image
Amylyx Pharmaceuticals
Price$4.61
Change+$0.03 (+0.66%)
Volume$989.96K
Capitalization410.94M
Erasca
Price$1.39
Change-$0.00 (-0.00%)
Volume$316
Capitalization393.77M
AMLX vs ERAS Comparison Chart
Loading...
AMLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMLX vs. ERAS commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a Hold and ERAS is a Hold.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (AMLX: $4.61 vs. ERAS: $1.39)
Brand notoriety: AMLX and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AMLX: 110% vs. ERAS: 31%
Market capitalization -- AMLX: $410.94M vs. ERAS: $393.77M
AMLX [@Biotechnology] is valued at $410.94M. ERAS’s [@Biotechnology] market capitalization is $393.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMLX’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • AMLX’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, AMLX is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMLX’s TA Score shows that 5 TA indicator(s) are bullish while ERAS’s TA Score has 7 bullish TA indicator(s).

  • AMLX’s TA Score: 5 bullish, 5 bearish.
  • ERAS’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than AMLX.

Price Growth

AMLX (@Biotechnology) experienced а -13.35% price change this week, while ERAS (@Biotechnology) price change was -12.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.25%. For the same industry, the average monthly price growth was +9.40%, and the average quarterly price growth was -13.49%.

Reported Earning Dates

AMLX is expected to report earnings on Aug 07, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-6.25% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMLX($411M) and ERAS($394M) have the same market capitalization . AMLX YTD gains are higher at: 21.958 vs. ERAS (-44.622). ERAS has higher annual earnings (EBITDA): -153.28M vs. AMLX (-290.98M). ERAS has more cash in the bank: 298M vs. AMLX (177M). AMLX has less debt than ERAS: AMLX (1.98M) vs ERAS (51.9M). AMLX has higher revenues than ERAS: AMLX (87.4M) vs ERAS (0).
AMLXERASAMLX / ERAS
Capitalization411M394M104%
EBITDA-290.98M-153.28M190%
Gain YTD21.958-44.622-49%
P/E Ratio2.81N/A-
Revenue87.4M0-
Total Cash177M298M59%
Total Debt1.98M51.9M4%
TECHNICAL ANALYSIS
Technical Analysis
AMLXERAS
RSI
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 9 days ago
76%
Bullish Trend 9 days ago
79%
Declines
ODDS (%)
Bearish Trend 5 days ago
82%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Ad is loading...
AMLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA298.2613.44
+4.72%
Tesla
GME27.540.76
+2.84%
GameStop Corp
AAPL198.531.04
+0.53%
Apple
SPY564.34-0.72
-0.13%
SPDR® S&P 500® ETF
BTC.X102970.850000-270.609380
-0.26%
Bitcoin cryptocurrency

AMLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMLX has been loosely correlated with ATRA. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if AMLX jumps, then ATRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMLX
1D Price
Change %
AMLX100%
+0.66%
ATRA - AMLX
65%
Loosely correlated
-2.02%
GRI - AMLX
57%
Loosely correlated
-8.13%
SLRX - AMLX
54%
Loosely correlated
-1.15%
RGNX - AMLX
47%
Loosely correlated
+5.17%
PRME - AMLX
43%
Loosely correlated
-1.52%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
N/A
XNCR - ERAS
57%
Loosely correlated
-5.23%
RVMD - ERAS
55%
Loosely correlated
-3.56%
KYMR - ERAS
55%
Loosely correlated
-2.27%
BEAM - ERAS
53%
Loosely correlated
+0.93%
RCKT - ERAS
52%
Loosely correlated
-0.71%
More